Who is sponsoring NCT01578447?

NCT01578447 is sponsored by Johns Hopkins Bloomberg School of Public Health.

What condition does NCT01578447 study?

NCT01578447 studies Acceptability of Different Contraceptive Injection Types.

What drugs are being tested in NCT01578447?

Interventions: DepoSubQ Provera 104 in Uniject, Intramuscular DMPA.

What is the status of NCT01578447?

NCT01578447 is currently COMPLETED.

Last reviewed 2014-09-16 · How we verify

Acceptability of Depo-subQ Provera 104 in Uniject Versus Intramuscular Depo-Provera Among HIV-positive Women and Family Planning Providers in Rakai, Uganda

NCT01578447 NA COMPLETED

The purpose of this study is to assess acceptability and side effects of a low-dose injectable contraceptive formulation which is delivered under the skin (subcutaneously), as compared with injectable contraception delivered into the muscle (intramuscularly) among adult HIV-positive women who attend mobile clinics for HIV care and wish to use injectable contraception. The investigators will also assess experiences experiences delivering these two types of injections among health care providers working within the HIV care clinics.

Details

Lead sponsor	Johns Hopkins Bloomberg School of Public Health
Phase	NA
Status	COMPLETED
Enrolment	356
Start date	2012-04
Completion	2013-03

Conditions

Acceptability of Different Contraceptive Injection Types

Interventions

DepoSubQ Provera 104 in Uniject
Intramuscular DMPA

Primary outcomes

Preferred injection method — 6 months
Preference for subcutaneous injection, intramuscular injection, or no preference between the two

Countries

Uganda